PCT/EP00/10649

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

Docket No.: P32451

Application Number

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## HYDROXAMIC ACID DERIVATIVE AS INHIBITOR OF THE FORMATION OF SOLUBLE HUMAN CD23

		CD23			
the specification of which (	(check one)				
[ ] is attached hereto.					
[X] was filed on 2	5 October 2000 as Seria	l No. PCT/EP00/10649			
and was amended	on (if applicable).				
•					
I hereby state that I have reviewed and understand the contents of the above identified specification,					
including the claims, as amended by any amendment referred to above.					
I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37.					
Code of Federal Regulations, Section 1.56.					
365(b) of any foreign application w	ication(s) for patent or in which designated at least of any foreign application f	ventor's certificate, or Secone country other than the for patent or Inventor's cer	United States, listed below and tificate, or PCT International		
Prior Foreign Application(s)					
Number	Country	Filing Date	Priority Claimed		
9925470.8	GB	27 October 1999	Yes		
I hereby claim the benefit	under Title 35, United St	tates Code, Section 119(e)	of any United States		

provisional application(s) listed belo	ow.

Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
Berrai Ivo.	I IIII Bate	Junio

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to Soma Simon, GlaxoSmithKline, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5019.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: John Gerard WARD

my from WarBate: 15th April 2002

Residence:

HARLOW, ESSEX, ENGLAND

Citizenship:

**BRITISH** 

Post Office Address:

GlaxoSmithKline

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939

alle: 15th April 2002

Full Name of Inventor: Andrew FALLER

Inventor's Signature:  $\underline{\bigvee}$ 

HARLOW, ESSEX, ENGLAND

Citizenship:

Residence:

**BRITISH** 

Post Office Address:

GlaxoSmithKline

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939